HOME >> BIOLOGY >> NEWS
Host response to anthrax lethal toxin suggests some current treatment strategies are inappropriate

Anthrax, a disease previously primarily relevant to the livestock-management community recently became a wordwide bioterrorism concern. However, human anthrax infection is primarily a result of direct or indirect contact with infected animals or exposure to contaminated animal products.

Bacillus anthracis, the causative agent of anthrax, is believed to induce disease and death in humans in an endotoxic shocklike manner. A comprehensive study of the effects of anthrax lethal toxin in mice by Stephen Leppla and colleagues at the National Institutes of Health demonstrated that toxin-induced death does not result from septic shock mediated by cytokine release as previously thought, but via hypoxia-induced liver failure. The study strongly suggests that the therapies developed for the treatment of cytokine-mediated septic shock will not be appropriate for the treatment of anthrax.

In an accompanying commentary, Alice Prince from Columbia University College of Physicians and Surgeons in New York states that "this analysis of the pathological effects of the B. anthracis lethal toxin should help focus future studies of optimal therapy for patients exposed to this organism. These results make clear that anthrax patients exhibit a unique pathophysiology and should not be considered to have generic shock analogous to Gram-negative sepsis". Prince continues "exactly how the lethal factor produces such profound tissue hypoxia, what metabolic processes are affected in the liver and elsewhere, and how these effects may be blocked will require further studies".


'"/>

Contact: Brooke Grindlinger
science_editor@the-jci.org
212-342-9006
Journal of Clinical Investigation
2-Sep-2003


Page: 1

Related biology news :

1. Columbia research to examine gene influence on severity of peridontal disease, therapy response
2. Protective gene may enhance vaccine responses
3. Activated signaling pathway may predict lung cancer patients response to gefitinib
4. Duke study disputes idea that trees can relocate quickly in response to climate change
5. Researchers develop better understanding of immune response to viral infection
6. Molecular motor shuttles key protein in response to light
7. Triple-vaccine strategy stimulates strong HIV-specific immune response in monkeys
8. Genetic basis for individual variations in the response to stress
9. Drunken worms reveal a genetic basis of alcohol response
10. Researchers identify genetic markers to predict response to chemotherapy for colorectal cancer
11. With fat, women have a more visceral response

Post Your Comments:
(Date:5/23/2013)... Frontiers, one of the world,s largest and fastest ... new journal, Frontiers in Bioengineering and Biotechnology ... all specialties, Frontiers in Bioengineering and Biotechnology ... diverse and emerging bioengineering and biotechnology research to ... in Bioengineering and Biotechnology will provide an ...
(Date:5/22/2013)... 22, 2013 U.S. Forest Service scientists are part ... funding from the TKF Foundation, will examine how collaborative ... individuals recover from tragedy. , The TKF Foundation announced ... projects selected for grant funding. In addition to research ... in recovery and resiliency, the 3-year, $585,000 grant will ...
(Date:5/22/2013)... developed a novel technique that can detect molecular variants ... is one of the most important, though time-consuming, processes ... paper in Nature , post-doctoral researcher David Patterson, ... of the Center for Free-Electron Laser Science (CFEL) in ... microwave fields to identify molecular variants apart, and to ...
Breaking Biology News(10 mins):Frontiers launches new open-access journal in Bioengineering and Biotechnology 2'Landscapes of Resilience' to study how people use nature as a source of recovery 2Detecting mirror molecules 2Detecting mirror molecules 3
(Date:5/23/2013)... , May 23, 2013  Rahal Letterman Lanigan Racing ... cord blood stem cell banking and therapeutics, announced today ... No. 16 Acorn Stairlifts Indy car driven by ... remainder of the IZOD IndyCar 2013 season.   ... work to support awareness of umbilical cord blood banking ...
(Date:5/23/2013)... Calif. , May 23, 2013 Virobay, ... treatment for pain has reached an important milestone, as ... of VBY-036 - a selective cathepsin S inhibitor.   ... is a double-blind, randomized, placebo-controlled study designed to evaluate ... of VBY-036 in healthy adults. "The initiation ...
(Date:5/23/2013)... DC (PRWEB) May 23, 2013 The ... in STEM industries, Black Data Processing Associates (BDPA), is ... on June 8, 2013. This all-day event will encourage ... and learn the ins and outs from many of ... 3 p.m. at the New Jersey Institute of Technology, ...
(Date:5/23/2013)... May 23, 2013 SynCardia Systems, Inc. ... only FDA, Health Canada and CE (Europe) approved Total ... in Scotland, which boasts more than 380,000 visitors annually, ... powered by the Freedom® portable driver as part ... most advanced exhibitions of its kind. , “BodyWorks ...
Breaking Biology Technology:StemCyte, Inc. Joins Rahal Letterman Lanigan Racing As Associate Sponsor Of No. 16 IndyCar Program For James Jakes Beginning With The 97th Indianapolis 500 2StemCyte, Inc. Joins Rahal Letterman Lanigan Racing As Associate Sponsor Of No. 16 IndyCar Program For James Jakes Beginning With The 97th Indianapolis 500 3Virobay, Inc. initiates a Phase 1 Trial of VBY-036, a compound intended for the treatment of neuropathic pain 2Virobay, Inc. initiates a Phase 1 Trial of VBY-036, a compound intended for the treatment of neuropathic pain 3Black Data Processing Associates (BDPA) New Jersey Hosts 10th Annual Families in Technology Day June 8, 2013 2SynCardia Total Artificial Heart Featured in $3 Million Exhibition at Glasgow Science Centre 2SynCardia Total Artificial Heart Featured in $3 Million Exhibition at Glasgow Science Centre 3
Cached News: